Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Conmed (CNMD) EBITDA (2016 - 2025)

Conmed's EBITDA history spans 16 years, with the latest figure at $19.7 million for Q4 2025.

  • For Q4 2025, EBITDA fell 33.56% year-over-year to $19.7 million; the TTM value through Dec 2025 reached $59.6 million, down 51.82%, while the annual FY2025 figure was $59.6 million, 51.82% down from the prior year.
  • EBITDA reached $19.7 million in Q4 2025 per CNMD's latest filing, up from $6.6 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $48.7 million in Q3 2024 to a low of -$172.6 million in Q2 2022.
  • Average EBITDA over 5 years is $12.2 million, with a median of $18.7 million recorded in 2021.
  • Peak YoY movement for EBITDA: soared 1058.34% in 2021, then plummeted 1072.98% in 2022.
  • A 5-year view of EBITDA shows it stood at $29.8 million in 2021, then decreased by 3.09% to $28.9 million in 2022, then grew by 27.72% to $36.9 million in 2023, then dropped by 19.66% to $29.6 million in 2024, then crashed by 33.56% to $19.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNMD's EBITDA are $19.7 million (Q4 2025), $6.6 million (Q3 2025), and $25.8 million (Q2 2025).